Q4 2025 Beyond Air Inc Earnings Call Transcript
Key Points
- Beyond Air Inc (XAIR) reported a 220% increase in revenue for the fiscal year ended March 31, 2025, reaching $3.7 million compared to $1.2 million the previous year.
- The company has provided revenue guidance of $12 million to $16 million for the fiscal year ending March 31, 2026, indicating strong growth expectations.
- Beyond Air Inc (XAIR) has established a solid customer base in key US regions, with several hospitals renewing contracts and new hospital starts.
- The company has expanded its international presence, securing distribution agreements in over two dozen countries, including India, Italy, and Israel.
- NeuroNOS, a subsidiary of Beyond Air Inc (XAIR), received Orphan Drug Designation from the US FDA for its lead investigational therapy, BA-102, for Phelan-McDermid syndrome.
- Despite revenue growth, Beyond Air Inc (XAIR) reported a net loss of $46.6 million for the fiscal year ended March 31, 2025.
- The cost of revenue exceeded revenue, primarily due to depreciation of LungFit devices and one-time upgrade costs.
- Research and development expenses, although reduced, were still significant at $16.9 million for fiscal year 2025.
- The company faces challenges in the international market, with longer tender processes and regulatory hurdles in some countries.
- Beyond Air Inc (XAIR) is not yet promoting its second-generation LungFit PH II system until FDA approval is obtained, which could delay potential market expansion.
Good afternoon, and welcome, everyone, to the Beyond Air financial results call for the fiscal quarter and year ended March 31, 2025. (Operator Instructions)
And now I would like to turn the call over to Corey Davis with LifeSci Advisors. Please go ahead.
Thank you, operator. Good afternoon, everyone, and thank you for joining us. Today, after the market closed, we issued a press release announcing the operational highlights and financial results for Beyond Air's fourth quarter of fiscal year 2025 ended March 31, 2025. A copy of this press release can be found on our website, beyondair.net, under the News & Events section.
Before we begin, I'd like to remind everyone that we will be making comments and various remarks about future expectations, plans and prospects, which constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.
Beyond Air cautions that these forward-looking statements are subject
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
